Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center

• Autor(a) principal: Daniela Oliveira de Lima Taranto
• Data de Publicação: 2020
• Outros Autores: Thais Cristine Moura Guimarães, Claudia Alves Couto, Ana Lúcia Cândido, Rosana Correa Silva Azevedo, Fernanda Souza Mattos, Maria Luiza Cândido Elias, Fernando Marcos dos Reis, Ana Luiza Lunardi Rocha, Luciana Costa Faria
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.20945/2359-3997000000242; http://hdl.handle.net/1843/56625; http://orcid.org/0000-0002-6641-1350; http://orcid.org/0000-0003-1014-0296; http://orcid.org/0000-0002-9776-4757; http://orcid.org/0000-0002-9080-2319; http://orcid.org/0000-0003-4676-7672; http://orcid.org/0000-0003-4364-7472; http://orcid.org/0000-0003-4504-4069; http://orcid.org/0000-0002-9258-7472; http://orcid.org/0000-0002-4717-9541; http://orcid.org/0000-0002-0226-3491
• topic: Polycystic ovary syndrome; Nonalcoholic fatty liver disease; Obesity; Insulin resistance; Liver fibrosis; Infertility; Síndrome do ovário policístico; Hepatopatia gordurosa não alcoólica; Obesidade; Resistência à insulina; Cirrose hepática; Infertilidade

Objective: Polycystic ovary syndrome (PCOS) is a recognized risk factor for nonalcoholic fatty liver disease (NAFLD). The aims of this study were to investigate the prevalence and factors associated with NAFLD in women with PCOS and evaluate noninvasive indices of hepatic fibrosis in patients with PCOS and NAFLD. Subjects and methods: Patients with PCOS (n = 87) and women without PCOS (n = 40; controls) were included. NAFLD was diagnosed by abdominal ultrasonography after exclusion of alcohol consumption and viral or autoimmune liver disease. Anthropometric, clinical and metabolic variables, homeostasis model assessment of insulin resistance (HOMA-IR) index, lipid accumulation product (LAP), FIB-4 index, NAFLD score, and transient elastography (TE; FibroScan) were obtained in subsets of patients with PCOS and NAFLD. Results: A total of 87 patients with PCOS were included (mean age: 34.4 ± 5.7 years, mean body mass index [BMI]: 34.7 ± 4.7 kg/m2). NAFLD was present in 67 (77.0%) patients with PCOS versus 21 of 40 (52.5%) controls (p = 0.005). Women with PCOS and liver steatosis, compared with their NAFLD-free counterparts, had higher values of BMI, waist circumference, triglycerides, total cholesterol, alanine and aspartate aminotransferases, and γ-glutamyltransferase, along with higher frequencies of obesity, metabolic syndrome, and insulin resistance. NAFLD was independently associated with waist circumference, serum triglycerides, and alanine aminotransferase levels. The FIB-4 index was not compatible with advanced fibrosis in any of the evaluated patients, while NAFLD score and TE were compatible with advanced liver fibrosis in 1 of 26 (3.8%) and 3 of 25 (12%) patients, respectively. Conclusion: Women with PCOS had a high risk of NAFLD, and a combination of both was associated with central obesity, dyslipidemia, insulin resistance, and metabolic syndrome. Noninvasive methods suggested low rates of severe hepatic fibrosis in Brazilian women with PCOS.